OCULOcular Therapeutix, Inc.

1. Aug 3, 2026Reports Second Quarter 2026 Financial Results and Business Highlights.Earnings release · press release
2. Jun 12, 2026Amendment to 2021 Stock Incentive Plan On June 10, 2026, Ocular Therapeutix, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”)Director or officer change · Form 8-K
3. May 5, 2026Ocular Therapeutix™ Reports First Quarter.Earnings release · press release
4. Feb 5, 2026Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights.Earnings release · press release
5. Jan 23, 2026Effective as of January 20, 2026, Donald Notman, Chief Financial Officer and Chief Operating Officer (principal financial officer and principal accounting officer) of Ocular Therapeutix, Inc. (the “Company”), is taking a temporary medical leave of absence from the Company.Director or officer change · Form 8-K
6. Dec 18, 2025As the Company prepares for database lock for its SOL-1 Phase 3 clinical trial of AXPAXLI (also known as OTX-TKI) for the treatment of wet age-related macular degeneration, the Company is entering a quiet period beginning December 20, 2025.Other event · Form 8-K
7. Dec 5, 2025The U.S. Food and Drug Administration (“FDA”) has historically required two adequate and well-controlled clinical trials to demonstrate the safety and efficacy of ophthalmic product candidates, in particular for larger indications such as wet age-related macular degeneration (“wet AMD”)Other event · Form 8-K
8. Nov 4, 2025Ocular Therapeutix™ Reports Third Quarter.Earnings release · press release
9. Sep 30, 2025On September 30, 2025, Ocular Therapeutix, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with BofA Securities, Inc., TD Securities (USA) LLC and Piper Sandler & Co., as representatives of the several underwriters named therein (the “Underwriters”), relating to an …Material agreement entered · Form 8-K
10. Sep 30, 2025On September 30, 2025, Ocular Therapeutix, Inc., or the Company, announced certain updates regarding its development programs for AXPAXLI (also known as OTX-TKI), the Company’s investigational, bioresorbable, intravitreal hydrogel incorporating axitinib, a small molecule, multi-target, tyrosine kinase inhibitor with …Other event · Form 8-K

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.